However, we have seen recent changes in the past hinting that Big Pharma is also showing signs of interest with rare diseases ...

The offering included about 8.5 million shares of Bayer, which is about 0.9% of the company. Initial reports stated that the ...

Gilead will pay $1.675 billion upfront plus up to $500 million in milestones to obtain OM336, positioning BCMA-targeted ...

In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its ...

High-sensitivity sequencing of recurrent, cell-type–specific variants aims to strengthen causal inference versus germline ...

Making changes in the pharma industry in operations is a slightly more expensive process because of larger compliances and ...

A Significant Shift in ASP Reporting. Beginning in 2026, CMS is requiring pharmaceutical manufacturers to submit “reasonable ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota ...

Acquired hypothalamic obesity is typically precipitated by hypothalamic insult from tumors, treatment, trauma, stroke, or ...

Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until ...

Matt Turner, President of Patient Affordability, Paysign discusses the evolving financial threats to pharmaceutical ...